Real-world Outcomes of Anti–Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States
[ad_1]
A co-authored study: Real-world nAMD patients in the US receive fewer anti-VEGF injections and experience worse visual outcomes compared with patients in randomized clinical trials…
http://www.ophthalmologyretina.org/article/S2468-6530(17)30297-X/fulltext
Real-world visual outcomes of anti–vascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration (nAMD) have been reported in cohorts outside of the United States. This study sought to assess the relationship between presenting visual acuity (VA) and visua…
[ad_2]
Return to main website.